Wnt, glucocorticoid and cellular prion protein cooperate to drive a mesenchymal phenotype with poor prognosis in colon cancer
© 2024. The Author(s)..
BACKGROUND: The mesenchymal subtype of colorectal cancer (CRC), associated with poor prognosis, is characterized by abundant expression of the cellular prion protein PrPC, which represents a candidate therapeutic target. How PrPC is induced in CRC remains elusive. This study aims to elucidate the signaling pathways governing PrPC expression and to shed light on the gene regulatory networks linked to PrPC.
METHODS: We performed in silico analyses on diverse datasets of in vitro, ex vivo and in vivo models of mouse CRC and patient cohorts. We mined ChIPseq studies and performed promoter analysis. CRC cell lines were manipulated through genetic and pharmacological approaches. We created mice combining conditional inactivation of Apc in intestinal epithelial cells and overexpression of the human prion protein gene PRNP. Bio-informatic analyses were carried out in two randomized control trials totalizing over 3000 CRC patients.
RESULTS: In silico analyses combined with cell-based assays identified the Wnt-β-catenin and glucocorticoid pathways as upstream regulators of PRNP expression, with subtle differences between mouse and human. We uncover multiple feedback loops between PrPC and these two pathways, which translate into an aggravation of CRC pathogenesis in mouse. In stage III CRC patients, the signature defined by PRNP-CTNNB1-NR3C1, encoding PrPC, β-catenin and the glucocorticoid receptor respectively, is overrepresented in the poor-prognosis, mesenchymal subtype and associates with reduced time to recurrence.
CONCLUSIONS: An unleashed PrPC-dependent vicious circle is pathognomonic of poor prognosis, mesenchymal CRC. Patients from this aggressive subtype of CRC may benefit from therapies targeting the PRNP-CTNNB1-NR3C1 axis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Journal of translational medicine - 22(2024), 1 vom: 08. Apr., Seite 337 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mouillet-Richard, Sophie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Beta Catenin |
|---|
| Anmerkungen: |
Date Completed 10.04.2024 Date Revised 11.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12967-024-05164-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM37079222X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM37079222X | ||
| 003 | DE-627 | ||
| 005 | 20240411232700.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240409s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12967-024-05164-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1372.xml |
| 035 | |a (DE-627)NLM37079222X | ||
| 035 | |a (NLM)38589873 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mouillet-Richard, Sophie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Wnt, glucocorticoid and cellular prion protein cooperate to drive a mesenchymal phenotype with poor prognosis in colon cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.04.2024 | ||
| 500 | |a Date Revised 11.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: The mesenchymal subtype of colorectal cancer (CRC), associated with poor prognosis, is characterized by abundant expression of the cellular prion protein PrPC, which represents a candidate therapeutic target. How PrPC is induced in CRC remains elusive. This study aims to elucidate the signaling pathways governing PrPC expression and to shed light on the gene regulatory networks linked to PrPC | ||
| 520 | |a METHODS: We performed in silico analyses on diverse datasets of in vitro, ex vivo and in vivo models of mouse CRC and patient cohorts. We mined ChIPseq studies and performed promoter analysis. CRC cell lines were manipulated through genetic and pharmacological approaches. We created mice combining conditional inactivation of Apc in intestinal epithelial cells and overexpression of the human prion protein gene PRNP. Bio-informatic analyses were carried out in two randomized control trials totalizing over 3000 CRC patients | ||
| 520 | |a RESULTS: In silico analyses combined with cell-based assays identified the Wnt-β-catenin and glucocorticoid pathways as upstream regulators of PRNP expression, with subtle differences between mouse and human. We uncover multiple feedback loops between PrPC and these two pathways, which translate into an aggravation of CRC pathogenesis in mouse. In stage III CRC patients, the signature defined by PRNP-CTNNB1-NR3C1, encoding PrPC, β-catenin and the glucocorticoid receptor respectively, is overrepresented in the poor-prognosis, mesenchymal subtype and associates with reduced time to recurrence | ||
| 520 | |a CONCLUSIONS: An unleashed PrPC-dependent vicious circle is pathognomonic of poor prognosis, mesenchymal CRC. Patients from this aggressive subtype of CRC may benefit from therapies targeting the PRNP-CTNNB1-NR3C1 axis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Colon cancer | |
| 650 | 4 | |a Glucocorticoid receptor | |
| 650 | 4 | |a Molecular classification | |
| 650 | 4 | |a Prion protein | |
| 650 | 4 | |a Wnt-β-catenin | |
| 650 | 7 | |a Prion Proteins |2 NLM | |
| 650 | 7 | |a beta Catenin |2 NLM | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 700 | 1 | |a Gougelet, Angélique |e verfasserin |4 aut | |
| 700 | 1 | |a Passet, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Brochard, Camille |e verfasserin |4 aut | |
| 700 | 1 | |a Le Corre, Delphine |e verfasserin |4 aut | |
| 700 | 1 | |a Pitasi, Caterina Luana |e verfasserin |4 aut | |
| 700 | 1 | |a Joubel, Camille |e verfasserin |4 aut | |
| 700 | 1 | |a Sroussi, Marine |e verfasserin |4 aut | |
| 700 | 1 | |a Gallois, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Lavergne, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Castille, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Vilotte, Marthe |e verfasserin |4 aut | |
| 700 | 1 | |a Daniel-Carlier, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Pilati, Camilla |e verfasserin |4 aut | |
| 700 | 1 | |a de Reyniès, Aurélien |e verfasserin |4 aut | |
| 700 | 1 | |a Djouadi, Fatima |e verfasserin |4 aut | |
| 700 | 1 | |a Colnot, Sabine |e verfasserin |4 aut | |
| 700 | 1 | |a André, Thierry |e verfasserin |4 aut | |
| 700 | 1 | |a Taieb, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Vilotte, Jean-Luc |e verfasserin |4 aut | |
| 700 | 1 | |a Romagnolo, Béatrice |e verfasserin |4 aut | |
| 700 | 1 | |a Laurent-Puig, Pierre |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of translational medicine |d 2003 |g 22(2024), 1 vom: 08. Apr., Seite 337 |w (DE-627)NLM142679194 |x 1479-5876 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2024 |g number:1 |g day:08 |g month:04 |g pages:337 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12967-024-05164-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2024 |e 1 |b 08 |c 04 |h 337 | ||